In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and ...

A new study published in the Journal of American Medical Association showed that reduced right ventricular ejection fraction ...

Nearly one-third of families of children receiving chemotherapy for acute lymphoblastic leukemia (ALL) develop serious ...

Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

An immunomodulatory vaccine advancing to phase 3 trials highlights the evolving role of immune system recalibration in cancer treatment. From immunotherapy breakthroughs to early-stage scientific ...

There is no coordinated system in place to help older adults and their families transition to long-term care and navigate the ...

AFSOS 2025 introduced the first European reference for photobiomodulation, outlining the evidence, dosing, and clinical use in supportive cancer care.

The pandemic phoneline system has been expanded to include two nurses per service across 26 hospitals in Ireland ...

Investigators evaluated outcomes for patients with pediatric AML with and without etoposide during first-line induction treatment.

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.